{"SPADE_UN_11349": {"Clinical Information": [{"Medical use": "Acute decompensated failure (ADHF),Organ failure", "Company": "Nile Therapeutics (United States, Minnesota).", "Stage of Development": "Phase II", "Comments": "CD-NP at 1.25 and 2.5 ng/kg/min appeared to preserve renal function relative to placebo as measured by renal biomarkers", "Clinical Trials": ["NCT00699712", "NCT00839007", "NCT02071602", "NCT02359227", "NCT02603614"]}], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_11349", "Peptide Name": "CD-NP(Cenderitide)", "Sequence": "GLSKGCFGLKLDRIGSMSGLGCPSLRDPRPDAPSTSA", "Source": "Synthetic chimeric 37-mer derived from combination of two natriuretic peptides", "Target Organism": "No MICs found on DRAMP database", "Reference": ["A PHASE II, DOSE-RANGING STUDY WITHÂ CD-NP, A CHIMERIC NATRIURETIC PEPTIDE, IN ACUTE DECOMPENSATED HEART FAILURE PATIENTS WITH RENAL COMPROMISE"], "Biological Activity": ["Unknown"], "Frequent Amino Acids": "GSL", "Absent Amino Acids": "EHNOQUVWY", "Basic Residues": 5, "Acidic Residues": 3, "Hydrophobic Residues": 14, "Polar Residues": 16, "Positive Residues": 5, "Negative Residues": 3, "Mass": 3748.27, "PI": 8.9, "Net Charge": 2, "Hydrophobicity": -0.25, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_01647", "Similarity": 0.5, "Sequence": "CLGLGLGCGLGLCLGLGLGLGLCGLGLGLCC"}]}}}